Keeping up with the pathogens: Improved antimicrobial resistance detection and prediction in

Pseudomonas aeruginosa

Danielle E. Madden[1,2], Timothy Baird[1,2,3], Scott C. Bell[4,5], Kate L. McCarthy[6,7], Erin P. Price[1,2*] and Derek
S. Sarovich[1,2*#]

[1]Centre for Bioinnovation, University of the Sunshine Coast, Sippy Downs, Queensland, Australia

[2]Sunshine Coast Health Institute, Birtinya, Queensland, Australia

[3]Respiratory Department, Sunshine Coast University Hospital, Birtinya, Queensland, Australia

[4]Adult Cystic Fibrosis Centre, The Prince Charles Hospital, Chermside, Queensland, Australia

[5]Children's Health Research Centre, Faculty of Medicine, The University of Queensland, South
Brisbane, Queensland, Australia

[6]University of Queensland Centre for Clinical Research, Herston, Queensland, Australia

[7]Royal Brisbane and Women's Hospital, Herston, Queensland, Australia

Keywords: Antibiotic, antimicrobial, resistance, AMR, whole-genome sequencing, high-throughput
sequencing, *Pseudomonas aeruginosa*, bioinformatics, database, efflux pumps

Running title: Antibiotic resistance detection from *P. aeruginosa* genomes

#Corresponding author:

Derek S. Sarovich

dsarovich@usc.edu.au; +61 7 5456 3748

*Authors contributed equally

Abstract

Background: Antimicrobial resistance (AMR) is an intensifying threat that requires urgent mitigation to avoid a post-antibiotic era. The bacterial pathogen, *Pseudomonas aeruginosa,* represents one of the greatest AMR concerns due to ever-increasing multi- and pan-drug resistance rates. Shotgun sequencing is gaining traction for AMR profiling due to its unambiguity and data transferability; however, existing tools for *in silico* AMR prediction perform poorly for this pathogen.

Methods: We curated the most comprehensive database to date of known *P. aeruginosa* AMR determinants. We then performed comparative genomics and microbial genome-wide association (mGWAS) across a Global isolate Dataset (n=1391) with paired antimicrobial phenotype and genome data to identify novel AMR determinants. Finally, we assessed the predictive performance of our ARDaP-implemented database, along with AMRFinderPlus and ResFinder, for both the Global Dataset and an additional Validation Dataset of 89 isolates.

Findings: Our AMR database of 754 chromosomal variants includes 79 newly discovered variants associated with AMR phenotype/s, and 246 variants in AMR-encoding loci that do not confer AMR. Interrogation of the Global Dataset with our AMR database achieved genotype-phenotype concordance (as measured by balanced accuracy [bACC]) of 86%, compared with bACCs of 57% with AMRFinderPlus and 63% with ResFinder. For the Validation Dataset, bACCs of 80%, 54%, and 53%, respectively, were attained.

Interpretation: Our pipeline provides the most accurate tool yet for AMR prediction in *P. aeruginosa*. Implementing our ARDaP-compatible AMR determinant database for routine AMR prediction from *P. aeruginosa* (meta)genomes will vastly improve AMR identification and treatment modalities, addressing a critical facet in combatting this treatment-refractory pathogen.

Funding: This work was supported by Advance Queensland (AQIRF0362018 and AQRF13016-17RD2), the Wishlist Sunshine Coast Health Foundation (2019-14), and the National Health and Medical

49   Research Council (GNT455919). The funders had no role in study design, data acquisition, analysis,

50   interpretation, writing, or manuscript submission.

52   Research in context

<u>Evidence before the study.</u> Several bioinformatic tools have been developed with the purpose of

facilitating rapid and accurate AMR prediction from microbial (meta)genomic data, particularly for

superbugs. To this end, we searched PubMed on July 29, 2022 using (((("pseudomonas aeruginosa")

AND ("antimicrobial resistance")) AND ("genome")) AND ("predict*")) NOT (review) for studies

published in all languages. Twenty-four results were obtained, of which 20 described the use of one or

more bioinformatic methods to predict AMR determinants (8 x ResFinder, 6 x CARD, 4 x comparative

genomics, 4 x machine learning, 2 x transcriptomics, 1 x OpGen internal bioinformatic pipeline). Only 1

study created an AMR determinant database, which demonstrated limited ability to predict AMR

across a dataset of 100 *P. aeruginosa* isolates. No study has yet created a publicly available, open-

source tool and associated AMR determinant database for widespread use.

<u>Added value of this study.</u> Our ARDaP-compatible AMR determinant database, which was built from

the largest-ever paired *P. aeruginosa* AMR phenotype-genome dataset to date (n=1480 isolates),

provides a crucial advancement in the way we use WGS data to rapidly and accurately predict AMR in

P. aeruginosa. Using ARDaP, systematic analysis of large volumes of WGS data can be used to develop

a more detailed understanding of the specific genetic variants that underpin AMR.

<u>Implications of all the available evidence.</u> AMR prediction tools will play an essential role in the battle

against superbugs as they provide precise information on the genetic basis of a pathogen's resistance

profile – information that can be used to inform timely antimicrobial-treatment shifts, reduce the

reliance on broad-spectrum antibiotics, and ultimately improve patient outcomes and slow the spread

of AMR. Our study demonstrates that predicting AMR phenotype from genotype in *P. aeruginosa* can

rival the performance of phenotypic AMR sensitivity testing such as the VITEK® 2, which is routinely

used in clinical microbiology laboratories worldwide. The rapid detection of emerging AMR and

multidrug resistance, and subsequent implementation of personalised treatment regimens, serves as

our best chance to extend antibiotic efficacy amidst the AMR crisis.

Introduction

Antimicrobial-resistant (AMR) infections are predicted to cause 10 million deaths globally by 2050 and cost USD$100 trillion per annum.[1] Antibiotic overuse and misuse[2] has driven the emergence of multi-drug resistant (MDR) bacteria globally.[3] We are now on the verge of a 'post-antibiotic era', where simple infections threaten to be untreatable with antimicrobials that once revolutionised modern medicine.[4]

Pseudomonas aeruginosa, a leading cause of nosocomial infections and an important community-acquired pathogen in people with chronic disease or immunosuppression, is associated with significant health and economic burden.[5] Intrinsically resistant to many antibiotics, *P. aeruginosa* can readily develop MDR via lateral gene transfer or chromosomal mutation.[6] This pathogen is one of the most difficult bacterial species from which to accurately predict AMR phenotype from genotype,[7] even using machine learning approaches,[8] with some current approaches as accurate as a coin toss.[7] Almost all existing AMR prediction tools have focused on detecting AMR gene gain[9,10] and a small cache of chromosomally encoded single-nucleotide polymorphisms (SNPs).[11-13] However, *P. aeruginosa* can also evolve AMR through insertions-deletions (indels), loss-of-function mutations (e.g. large deletions or frameshift mutations), and copy-number variations (CNVs).[14] Despite recent advances,[10,11] most AMR tools remain limited in their scope and accuracy[15] – for example, loss-of-function mutations are largely ignored,[13] AMR databases are often not species-specific,[13,16] resolution is limited to antibiotic class,[10] and precursor mutations conferring reduced antimicrobial susceptibility are overlooked. These limitations are especially problematic for accurate AMR detection in pathogens encoding complex resistomes like *P. aeruginosa*.[7]

To address this knowledge gap, we curated and validated a comprehensive *P. aeruginosa*-specific AMR determinant database, which, when used in conjunction with the Antimicrobial Resistance Detection and Prediction (ARDaP) software,[13] enables high-accuracy AMR prediction from *P. aeruginosa* (meta)genomes. Performance of our ARDaP-compatible AMR determinant database was first assessed across 1391 geographically diverse *P. aeruginosa* strains ("Global Dataset"), and subsequently, across

103   89 analysis-naïve Australian *P. aeruginosa* strains ("Validation Dataset"). Our approach, which we

104   demonstrate exceeds the performance to current 'gold standard' AMR prediction software, provides a

105   crucial steppingstone towards the routine clinical use of (meta)genomics to inform personalised

106   treatment, such as in response to AMR evolution.

Methods

Global Dataset. To comprehensively capture geographic and phenotypic diversity, we collated a large and comprehensive *P. aeruginosa* isolate collection (*n*=1391) by identifying all publicly available strains with paired antimicrobial phenotype and whole-genome sequence (WGS) data (Tables S1 and S2, and Figure S1). Ten clinically relevant antibiotics (amikacin, cefepime, ceftazidime, ciprofloxacin, colistin, imipenem, meropenem, tobramycin, piperacillin, and piperacillin/tazobactam), representing six antibiotic classes (aminoglycosides, β-lactams, carbapenems, cephalosporins, fluoroquinolones, and polymyxins), were assessed (Table 1), including a substantial number of antimicrobial-susceptible strains, which are essential for developing and refining high-quality AMR databases.[13,17]. Where possible, isolates with minimum inhibitory concentration (MIC) data were reclassified as sensitive, intermediate, or resistant using the CLSI M100S-Ed32:2022 guidelines.

Validation Dataset. To independently evaluate AMR prediction software performance, we examined a collection of 89 phylogenetically diverse Australian clinical *P. aeruginosa* strains (Figure S2). Isolates were obtained from people admitted to hospital with cystic fibrosis (CF [sputum]; *n*=42), bloodstream infection (*n*=35), chronic obstructive pulmonary disease (COPD [sputum]; *n*=8), non-CF bronchiectasis (sputum; *n*=1), ear infection (*n*=1), ulcer (*n*=1), or urinary tract infection (*n*=1), between 2008 and 2020. Eighty-four isolates have previously been subjected to WGS (NCBI BioProject PRJNA761496; GenBank accessions NSXK00000000.1 and NSZK00000000.1) and some antimicrobial susceptibility testing;[18,19] five additional COPD isolates were sequenced, and all isolates underwent antimicrobial susceptibility testing across the 10 examined antibiotics (Table S3), for the current study. *P. aeruginosa* strains PAO1 and LMG 6395 were included as antimicrobial-susceptible controls. Clinical specimen collection was approved by The Prince Charles Hospital (HREC/13/QPCH/127 and HREC/2019/QPCH/48013) and Royal Brisbane and Women's Hospital (DA: jl) Human Research Ethics Committees. Participants with CF or COPD provided written consent; a waiver of informed consent was approved for other specimens due to a low-to-negligible risk assessment.

AMR profiling. Antimicrobial susceptibility profiles for 8 of 10 clinically relevant antibiotics were

determined across the Validation Dataset (Table S3) using disc diffusions. Isolates were classed as

sensitive, intermediate or resistance using CLSI M100S-Ed32:2022 guidelines. Meropenem and

ciprofloxacin MICs were determined using ETESTs (bioMérieux, Murarrie, Australia) using sensitive,

intermediate, and resistant MIC cut-offs of ≤4, 8, and ≥16 µg/mL for meropenem, and ≤0.5, 1, and ≥2

µg/mL for ciprofloxacin.

P. aeruginosa **ARDaP database construction.** Gene names, locus tags and genomic coordinates in our

AMR determinant database were based on the archetypal genome, PAO1 (NC_002516.2). To identify

AMR determinants, a thorough literature search was conducted, and an ARDaP v1.9[13] compatible

SQLite database was populated. We then augmented this database by performing a microbial

genome-wide association study (mGWAS), along with a comprehensive comparative genomic analysis,

on the Global Dataset, to identify previously unidentified AMR determinants in *P. aeruginosa*. Our

AMR database also contains a modified version of the ResFinder database,[9] in which ubiquitous genes

in *P. aeruginosa* have been removed, and additional genes included, to reduce noise and improve

prediction accuracy. Detailed descriptions of each of these steps are described in the Supplemental

Methods. All additional scripts used in this study, including those used for mGWAS analysis, are

available at: github.com/dsarov/P_aeruginosa_ARDaP_manuscript.

AMR prediction analysis. AMR prediction in the Global and Validation Datasets was performed using

our *P. aeruginosa* AMR database (v1.0), implemented in ARDaP. ARDaP was chosen as it is the only

AMR software that can detect all mutation types (i.e. SNPs, indels, gene loss, frameshift mutations,

structural variants, and CNVs).[13] ARDaP performance was compared against three well-known, 'gold

standard' AMR detection tools: RGI v5.1.0 and CARD v3.0.9,[10] ResFinder v4.1,[9] and AMRFinderPlus

v3.8.28.[20] ARDaP software and the complete *P. aeruginosa* AMR database are available at:

github.com/dsarov/ARDaP.

AMR software predictive performance in *P. aeruginosa*. ARDaP, AMRFinderPlus, CARD, and

ResFinder predictions from isolate genomes were compared against their corresponding phenotypic

AMR profiles. Due to its inability to predict AMR towards individual antibiotics, and a very high rate of

false-positive predictions in the Global Dataset, CARD was deemed unsuitable for *P. aeruginosa* AMR

analysis and was therefore excluded from the Validation Dataset analysis. As most AMR prediction

software does not predict intermediate resistance, we excluded strains with this classification, and

removed intermediate AMR determinants from our ARDaP-compatible database, when performing

software comparisons. Predictive performance was determined using balanced accuracy (bACC),[21]

which averages sensitivity [i.e. true positives/(true positives + true negatives)], and specificity [i.e. true

negatives/(true negatives + false positives)]. This metric was chosen as it accounts for dataset

imbalance; that is, it minimises over- or under- representation of antimicrobial-sensitive or AMR

strains that may otherwise make certain tools appear better or worse due to dataset bias.

Intermediate resistance prediction. The capacity of our ARDaP-compatible AMR determinant

database to predict intermediate resistance phenotypes was examined in the Global Dataset. The

following rules were applied during software evaluation: 1) A true-positive prediction occurred when

either: i) an AMR strain was classed as AMR, or ii) an intermediate strain was classed as intermediate.

2) A true-negative prediction occurred when an antimicrobial sensitive strain was classed as

antimicrobial sensitive. 3) A false-positive prediction occurred when either: i) a sensitive strain was

classed as intermediate or AMR, or ii) an intermediate strain was classed as AMR. 4) A false-negative

prediction occurred when either: i) an intermediate strain was classed as sensitive, or when an AMR

strain was predicted to be antimicrobial sensitive or intermediate. These rules provided the strictest

evaluation criteria for the assessment of ARDaP's ability to identify intermediate strains.

Results

Novel *P. aeruginosa* AMR determinant identification and refinement. Among the 675 published

chromosomal AMR variants that we identified from the literature, we classified 246 (36%) as 'natural

variation' as they were common in both antimicrobial-sensitive and AMR strains, and thus not

associated with conferring an AMR phenotype towards any of the 10 tested antibiotics (Table S4).

Next, we identified novel AMR variants by examining all chromosomal variants occurring in known

AMR loci in the Global Dataset using mGWAS and comparative genomics. This analysis identified 79

previously unreported putative AMR determinants, each of which were significantly associated with

one or more AMR phenotypes (Table 2). In total, we identified 754 variants in known AMR loci, of

which 508 were confirmed or predicted to be associated with AMR. Upon retesting of our refined

ARDaP-compatible AMR database with the additional 79 novel AMR determinants, our database's

average bACC value across the 10 antibiotics increased from 82% to 86%.

Predictive performance of AMR software across the Global Dataset. The predictive performance of

AMRFinderPlus, CARD, and ResFinder was evaluated in the Global Dataset. Although superior to CARD,

ResFinder and AMRFinderPlus still showed relatively poor bACCs for most antibiotics. Of these two

tools, ResFinder was more accurate, with an average bACC of 63%, compared with AMRFinderPlus,

with an average bACC of just 57%. However, both tools performed well below ARDaP's average bACC

of 86% (Figure 1A).

The best ResFinder and AMRFinderPlus predictions were achieved for the aminoglycosides, with

average bACCs of 85% and 73%, respectively, although these rates were lower than ARDaP at an

average aminoglycoside bACC of 89%. AMR prediction for all other antibiotics using ResFinder and

AMRFinderPlus showed poor to very poor bACCs. AMRFinderPlus had a bACC of just 50% for the

penicillins, cephalosporins, and colistin – the same predictive capacity as a coin flip – and had only

slightly better bACCs for ciprofloxacin (53%) and carbapenems (61%). ResFinder also had a bACC of

just 50% for cephalosporins and colistin, and performed worse for carbapenems (average bACC of

56%) than AMRFinderPlus, although it was better for penicillins (average bACC of 71%) and

ciprofloxacin (bACC of 60%). In contrast, ARDaP surpassed ResFinder and AMRFinderPlus across the

penicillins, cephalosporins, carbapenems, ciprofloxacin, and colistin, with bACCs ranging from 70% for

colistin to 90% for ciprofloxacin (Figure 1A).

Predictive performance of AMR software across the Validation Dataset. We next tested

AMRFinderPlus, ResFinder, and our ARDaP-compatible AMR database across the Validation Dataset of

89 Australian clinical *P. aeruginosa* strains (Table S2) to determine each software's performance in an

analysis-naïve dataset. These strains exhibited similar AMR rates to the Global Dataset, ranging from

0% for colistin to 61% for piperacillin (Figure S2; Table S3). As no strains in the Validation Dataset

displayed colistin AMR, the bACC for this antibiotic could not be assessed.

Overall, our ARDaP-compatible database had high predictive accuracy (average bACC of 80%) across all

antibiotics (Figure 1B), vastly outperforming AMRFinderPlus (average bACC of 54%) and ResFinder

(average bACC of 53%), which, once again, were only marginally better in their predictive capacity

than a coin flip. Of note is the ResFinder meropenem bACC value, which, at just 45%, was worse than a

coin flip.

ARDaP AMR prediction comparison between the Global and Validation Datasets. Although the

ARDaP bACCs between the Validation and Global Datasets were similar, there was a greater

proportion of false-positive/false-negative determinants encoding piperacillin (19% difference),

amikacin and tobramycin (16% difference), cefepime (11% difference), and meropenem (8%

difference) AMR in the Validation Dataset. In contrast, there was a greater proportion of false-

positive/false-negative determinants encoding ciprofloxacin AMR (4% difference) in the Global Dataset

(Figure 1).

Comparative genomic analysis of Validation Dataset isolates with false-negative predictions for

aminoglycoside resistance identified clade-specific SNPs in all sequence type (ST) 801 isolates, which

occurred in elongation factor G (*fusA1*; D427G, S459F, G632A and R658H). Inclusion of these SNPs

significantly increased the ARDaP bACC values by 15% for both amikacin and tobramycin, raising them

to 87% and 94%, respectively.

Precision and recall metrics among AMR software. Our ARDaP-compatible database demonstrated

excellent average precision and recall for predicting antimicrobial-sensitive and AMR phenotypes,

ranging from 79% (average AMR recall) to 92% (average sensitivity precision and sensitivity recall)

(Figure S3A). In contrast, ResFinder's metrics ranged from only 49% (average sensitivity precision) to

65% (average AMR precision) (Figure S3B), and AMRFinderPlus's metrics ranged from 58% (average

sensitivity precision) to 67% (average sensitivity recall) (Figure S3C).

For colistin, AMRFinderPlus and ResFinder both yielded AMR precision and recall values of 0%; in

other words, neither of these tools identified colistin AMR determinants in strains exhibiting a colistin

AMR phenotype, whereas our ARDaP-compatible database identified colistin AMR strains with 41%

recall and 100% precision. Similarly, AMRFinderPlus and ResFinder failed to predict cefepime

sensitivity in any cefepime-sensitive strains, instead erroneously classing every strain as cefepime-

resistant, whereas ARDaP correctly identified cefepime-sensitive strains 91% precision and 93% recall

(Figure S3A). AMRFinderPlus also failed to identify piperacillin or piperacillin/tazobactam sensitivity in

any of the tested strains (Figure S3C).

Predictive performance for intermediate resistance. The inclusion of isolates with intermediate

resistance (i.e. strains with decreased susceptibility but not classed as full AMR; Table S5), reduced our

ARDaP-compatible database's bACC values by between 1 to 14%, depending on the antibiotic.

Intermediate resistance inclusion was most detrimental to cefepime AMR prediction (-14%), followed

by meropenem (-10%), ceftazidime, ciprofloxacin, and piperacillin (-9%), amikacin and

piperacillin/tazobactam (-7%), colistin (-5%), imipenem (-3%), and tobramycin (-1%).

Discussion

The increasing role of high-throughput sequencing in the delivery of clinical care has driven the concomitant development of bioinformatic tools for AMR prediction.[22] However, despite much hope and hype, almost all AMR prediction tools remain limited in their accuracy and performance, in large part due to their inability to detect the gamut of variants that can confer AMR, along with their lack of chromosomally encoded determinants.[13] This shortcoming becomes most evident when attempting to predict AMR in pathogens with complex resistomes such as *P. aeruginosa*[7].

To address this issue, we constructed the most comprehensive database yet of known AMR determinants in *P. aeruginosa*, which was augmented with 79 putative novel AMR determinants identified using comparative genomics and mGWAS. In addition, we included 246 non-AMR-conferring variants, which have been reported as potentially AMR-conferring in prior published studies. Whilst the addition of these natural variants did not directly improve our database's predictive performance, their inclusion was invaluable for reducing the legwork in identifying putative novel AMR variants, and will help minimise erroneously reported putative novel AMR variants in future studies. We then tested our *P. aeruginosa* AMR database across 1480 *P. aeruginosa* genomes using ARDaP, the only AMR software that can detect all AMR-conferring genetic variants.[13] When measured across several performance metrics (bACC, precision and recall), our ARDaP-implemented database far outstrips the AMR predictive performance of 'gold standard' AMR prediction tools, AMRFinderPlus, CARD, and ResFinder, across 10 clinically relevant antibiotics, and in both the Global and Validation Datasets (Figure 1). Our findings concur with a prior study of 654 *P. aeruginosa* genomes, which also showed that CARD and ResFinder exhibited poor performance metrics across all 11 tested anti-pseudomonal antibiotics.[7]

Among the antibiotic classes, AMRFinderPlus and ResFinder performed best for aminoglycosides in the Global Dataset (Figure 1A), which is heavily weighted towards American and European strains (Table S2). However, these two tools performed substantially worse for the Australian Validation Dataset (Figure 1B), with average aminoglycoside bACC values dropping by 15% for AMRFinderPlus and 27%

for ResFinder. The bACC was also lowered by 15% with our ARDaP-implemented database,

predominantly due to ST801 isolates calling as false-negatives. Inclusion of the novel *fusA1* SNPs

restored this performance to bACC values of 87% and 94% for amikacin and tobramycin, respectively.

This performance difference across isolate datasets can be attributed to two phenomena. The first is

the predominance of aminoglycoside-modifying enzymes in the Global (27% prevalence), but not

Validation (8% prevalence) Datasets, reflecting potential major differences in the geographic

prevalence of these enzymes that requires further exploration. The second is the enrichment of cystic

fibrosis-derived isolates, which comprise 93% of the aminoglycoside AMR strains, in the Validation

Dataset. These isolates have largely developed aminoglycoside AMR via chromosomal mutation rather

than aminoglycoside-modifying enzyme acquisition; as such, AMRFinderPlus and ResFinder had poor

aminoglycoside AMR predictive capacity in this dataset due to their limited chromosomal AMR variant

databases. These performance differences highlight the need for including isolates from diverse

sources, disease states, and locales to provide the most relevant AMR prediction software

benchmarking comparisons. Our results suggest that AMRFinderPlus and ResFinder are not useful for

predicting aminoglycoside AMR from cystic fibrosis-derived *P. aeruginosa*, although this finding

requires further exploration across larger and geographically diverse datasets.

Chromosomally-encoded loss-of-function mutations affecting the specialised porin, OprD, are the

most common cause of carbapenem AMR in *P. aeruginosa*, particularly in clinical isolates.[8] Although

oprD is notoriously hypervariable,[23] the ability to accurately identify functional OprD loss accounted

the high predictive accuracy for carbapenem AMR seen with ARDaP (average bACC of 89% vs. just 61%

for AMRFinderPlus and 52% for ResFinder). This outcome demonstrates the complex nature of the *P.*

aeruginosa resistome, the often-overlooked necessity of manual AMR variant curation efforts, and the

value of species-specific AMR variant databases to achieve the most accurate AMR predictions.

Mutations leading to chromosomal cephalosporinase (*ampC*) overexpression are an important cause

of β-lactam AMR, which includes the penicillins and cephalosporins.[14,24] To predict *ampC* upregulation,

our database includes function-altering mutations in genes known to regulate *ampC*, either directly or

indirectly. These chromosomally-encoded variants, alongside acquired cephalosporinases, accounted

for the high average ARDaP bACC observed for the cephalosporins (85% vs. just 50% with

AMRFinderPlus and ResFinder; Figure 1). The prominence of *ampC* over-expression provides further

support that this mechanism is a major cause of acquired cephalosporin AMR, particularly in clinical *P.*

aeruginosa isolates.[24,25] In support of this hypothesis, Khaledi and colleagues demonstrated a

considerably higher bACC for ceftazidime AMR prediction when using both transcriptomic and WGS

data (82%) compared with just WGS data (67%).[8] WGS alone therefore cannot currently identify all

instances of *ampC* over-expression, either because up-regulation is the result of an epigenic change, or

the mutation remains cryptic due to an incomplete understanding of *ampC* regulatory mechanisms.

Regardless, combining WGS alongside transcriptomic data will likely lead to improved AMR prediction

for most antibiotics.[8,24]

Predicting intermediate resistance is exceedingly difficult from WGS data alone, even with complex

machine learning algorithms that combine transcriptomic and WGS data.[8] We also encountered

difficulties with predicting intermediate resistance, with the inclusion of intermediate strains dropping

the bACC value by up to 14% (Table S5). Possible explanations for this prediction difficulty include the

need to understand the contribution of stepwise variants in conferring decreased antibiotic

susceptibility,[14,26,27] subtle and rapidly reversible gene expression alterations[8] caused by methylation[28]

or dynamic environmental stimuli, and undetected strain mixtures. Further refinement of our ARDaP-

compatible database, such as including capacity to interpret RNA-seq data, will continue to improve

this critical yet understudied area. Nevertheless, the pioneering capacity of ARDaP to predict

intermediate resistance, including stepwise mutations that lower the barrier to full AMR development,

has important implications for detecting emerging AMR in *P. aeruginosa* isolates. The eventual goal

will be to use this information to inform early treatment shifts to improve patient survival.[13]

We were unable to predict AMR with a 100% bACC value for any antibiotic. Errors introduced during

sample collection, metadata curation, specimen processing, or sequencing may partially account for

these discrepancies. For example, 11 strains in the Khaledi *et al.* dataset possessed determinants

known to confer ceftazidime AMR (e.g. $bla_{VIM-[2,4,47]}$, bla_{OXA-2}, $bla_{GES-[1,5]}$) yet were reported as

ceftazidime sensitive, and 22 strains in the Kos *et al.* dataset were amikacin sensitive, yet possessed

the aminoglycoside-modifying enzyme *aac*(6')-Ib-cr, known to cause amikacin AMR and reduced

ciprofloxacin susceptibility.[29] Due to the presence of these determinants, ARDaP, AMRFinderPlus, and

ResFinder all identified these strains as AMR, contributing to imperfect bACC values (Figure 1) and

poor precision (Figure S3) for amikacin and ceftazidime across all tools. As we did not have access to

these strains, it was not possible to retest their AMR phenotypes or to repeat WGS; however, we

hypothesise that these strains would generate different results upon phenotypic retesting.

Alternatively, these AMR determinants may be present in the genome but are functionally or

transcriptionally inactive, resulting in false-positive predictions for these isolates that must be factored

into AMR prediction estimates.

We recognise several study limitations. Some false-positive predictions were identified across all

antibiotic classes with our ARDaP-compatible database; however, these rates were significantly lower

than those reported by other software (Figure 1). Whilst not ideal, we have included some AMR

determinants that result in false-positive predictions at a relatively low frequency. These were not

removed from the final database because: i) false positives may occur as some strains revert to the

sensitive phenotype despite encoding a known AMR determinant, and ii) we relied on phenotypic data

provided by others, which may harbour inaccuracies. Our study would have benefitted from the

inclusion of transcriptomic data to augment our WGS data.[8] Although our understanding of the

molecular mechanisms of AMR in *P. aeruginosa* is improving rapidly in the genomics era, false-

negative predictions still occur across all antibiotic classes. Excitingly, these false-negative strains can

now be rapidly identified and targeted for future molecular work to identify novel AMR determinants

and mechanisms.

Acknowledgements

We wish to thank Jane Neill (Sunshine Coast Hospital and Health Service, Sunshine Coast University

Hospital) for providing the chronic obstructive pulmonary samples used in this study, and Kay Ramsay

(University of Queensland) and Tamieka Fraser (University of the Sunshine Coast) for laboratory

support.

Author contributions

DEM drafted the initial manuscript, compiled the original *P. aeruginosa* AMR determinant database,

performed data analyses and laboratory work, and assisted with ARDaP software refinement; TB

provided chronic obstructive pulmonary disease respiratory specimens that were used to retrieve *P.*

aeruginosa isolates, assisted with obtaining ethics approvals for sputum and bronchial washing

collection, and obtained study funding; SCB provided cystic fibrosis sputa that were used to retrieve *P.*

aeruginosa isolates, and obtained ethics approval for sputum collection; KM provided bloodstream *P.*

aeruginosa isolates, and obtained ethics approval for blood collection; EPP assisted with study

conception, obtaining and overseeing ethics approvals, manuscript preparation, data analyses and

laboratory work, provided student supervision, obtained study funding, and assisted with curation of

the natural variant database; and DSS conceived of the study, wrote the ARDaP software, refined the

P. aeruginosa AMR determinant database, assisted with manuscript preparation, data analyses and

laboratory work, provided student supervision, and obtained study funding. All authors read and

approved of the final manuscript.

Conflicts of interest

The authors declare no conflicts of interest.

References

1.   O'Neill JC. Antimicrobial resistance: Tackling a crisis for the health and wealth of nations 2014
[Available from: https://amr-review.org/Publications.html.
2.   Mancuso G, Midiri A, Gerace E, Biondo C. Bacterial antibiotic resistance: The most critical
pathogens. *Pathogens* 2021;**10**: 1310.
3.   Bassetti M, Merelli M, Temperoni C, Astilean A. New antibiotics for bad bugs: where are we?
Ann Clin Microbiol Antimicrob 2013;**12**: 22.
4.   Alanis AJ. Resistance to antibiotics: are we in the post-antibiotic era? *Arch Med Res* 2005;**36**:
697-705.
5.   Zhen X, Lundborg CS, Sun X, Hu X, Dong H. Economic burden of antibiotic resistance in ESKAPE
organisms: a systematic review. *Antimicrob Resist Infect Control* 2019;**8**: 137.
6.   Breidenstein EB, de la Fuente-Nunez C, Hancock RE. *Pseudomonas aeruginosa*: All roads lead
to resistance. *Trends Microbiol* 2011;**19**: 419-426.
7.   Mahfouz N, Ferreira I, Beisken S, von Haeseler A, Posch AE. Large-scale assessment of
antimicrobial resistance marker databases for genetic phenotype prediction: a systematic review. *J
Antimicrob Chemother* 2020;**75**: 3099-3108.
8.   Khaledi A, Weimann A, Schniederjans M, Asgari E, Kuo T-H, Oliver A, et al. Predicting
antimicrobial resistance in *Pseudomonas aeruginosa* with machine learning-enabled molecular
diagnostics. *EMBO Mol Med* 2020;**12**: e10264.
9.   Bortolaia V, Kaas RS, Ruppe E, Roberts MC, Schwarz S, Cattoir V, et al. ResFinder 4.0 for
predictions of phenotypes from genotypes. *J Antimicrob Chemother* 2020;**75**: 3491-3500.
10.   Alcock BP, Raphenya AR, Lau TTY, Tsang KK, Bouchard M, Edalatmand A, et al. CARD 2020:
antibiotic resistome surveillance with the comprehensive antibiotic resistance database. *Nucleic Acids
Res* 2019;**48**: D517-D525.
11.   Hunt M, Mather AE, Sanchez-Buso L, Page AJ, Parkhill J, Keane JA, et al. ARIBA: Rapid
antimicrobial resistance genotyping directly from sequencing reads. *Microb Genom* 2017;**3**: e000131.
12.   Zankari E, Allesoe R, Joensen KG, Cavaco LM, Lund O, Aarestrup FM. PointFinder: A novel web
tool for WGS-based detection of antimicrobial resistance associated with chromosomal point
mutations in bacterial pathogens. *J Antimicrob Chemother* 2017;**72**: 2764-2768.
13.   Madden DE, Webb JR, Steinig EJ, Currie BJ, Price EP, Sarovich DS. Taking the next-gen step:
Comprehensive antimicrobial resistance detection from *Burkholderia pseudomallei*. *EBioMedicine*
2021;**63**: 103152.
14.   Lister PD, Wolter DJ, Hanson ND. Antibacterial-resistant *Pseudomonas aeruginosa*: Clinical
impact and complex regulation of chromosomally encoded resistance mechanisms. *Clin Microbiol Rev*
2009;**22**: 582-610.
15.   Pesesky MW, Hussain T, Wallace M, Patel S, Andleeb S, Burnham CD, et al. Evaluation of
machine learning and rules-based approaches for predicting antimicrobial resistance profiles in Gram-
negative Bacilli from whole genome sequence data. *Front Microbiol* 2016;**7**: 1887.
16.   Gupta SK, Padmanabhan BR, Diene SM, Lopez-Rojas R, Kempf M, Landraud L, et al. ARG-
ANNOT, a new bioinformatic tool to discover antibiotic resistance genes in bacterial genomes.
Antimicrob Agents Chemother 2014;**58**: 212-220.
17.   Su M, Satola SW, Read TD. Genome-based prediction of bacterial antibiotic resistance. *J Clin
Microbiol* 2019;**57**: e01405-18.
18.   Madden DE, McCarthy KL, Bell SC, Olagoke O, Baird T, Neill J, et al. Rapid fluoroquinolone
resistance detection in *Pseudomonas aeruginosa* using mismatch amplification mutation assay-based
real-time PCR. *J Med Microbiol* 2021;**In Press**.
19.   Madden DE, Olagoke O, Baird T, Neill J, Ramsay KA, Fraser TA, et al. Express yourself:
Quantitative real-time PCR assays for rapid chromosomal antimicrobial resistance detection in
Pseudomonas aeruginosa. *Antimicrob Agents Chemother* 2022;**66**: e0020422.

20.   Feldgarden M, Brover V, Haft DH, Prasad AB, Slotta DJ, Tolstoy I, et al. Validating the
AMRFinder tool and resistance gene database by using antimicrobial resistance genotype-phenotype
correlations in a collection of isolates. *Antimicrob Agents Chemother* 2019;**63**: e00483-19.
21.   Bekkar M, Djemaa HK, Alitouche TA. Evaluation measures for models assessment over
imbalanced data sets. *J Inf Eng Appl* 2013;**3**: 27-38.
22.   Van Goethem N, Descamps T, Devleesschauwer B, Roosens NHC, Boon NAM, Van Oyen H, et
al. Status and potential of bacterial genomics for public health practice: a scoping review. *Implement*
Sci 2019;**14**: 79.
23.   Li H, Luo YF, Williams BJ, Blackwell TS, Xie CM. Structure and function of OprD protein in
Pseudomonas aeruginosa: from antibiotic resistance to novel therapies. *Int J Med Microbiol* 2012;**302**:
63-68.
24.   Cabot G, Ocampo-Sosa AA, Tubau F, Macia MD, Rodriguez C, Moya B, et al. Overexpression of
AmpC and efflux pumps in *Pseudomonas aeruginosa* isolates from bloodstream infections: prevalence
and impact on resistance in a Spanish multicenter study. *Antimicrob Agents Chemother* 2011;**55**: 1906-
1911.
25.   Lee JY, Ko KS. OprD mutations and inactivation, expression of efflux pumps and AmpC, and
metallo-β-lactamases in carbapenem-resistant *Pseudomonas aeruginosa* isolates from South Korea.
Int J Antimicrob Agents 2012;**40**: 168-172.
26.   Levy SB, Bonnie M. Antibacterial resistance worldwide: Causes, challenges and responses.
Nature Medicine 2004;**10**: S122-S129.
27.   Rehman A, Jeukens J, Levesque RC, Lamont IL. Gene-gene interactions dictate ciprofloxacin
resistance in *Pseudomonas aeruginosa* and facilitate prediction of resistance phenotype from genome
sequence data. *Antimicrob Agents Chemother* 2021;**65**: e0269620.
28.   Law COK, Huang C, Pan Q, Lee J, Hao Q, Chan T-F, et al. A small RNA transforms the multidrug
resistance of *Pseudomonas aeruginosa* to drug susceptibility. *Mol Ther Nucleic Acids* 2019;**16**: 218-
228.
29.   Robicsek A, Strahilevitz J, Jacoby GA, Macielag M, Abbanat D, Park CH, et al. Fluoroquinolone-
modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. *Nat Med*
2006;**12**: 83-88.
30.   Dötsch A, Becker T, Pommerenke C, Magnowska Z, Jänsch L, Häussler S. Genomewide
identification of genetic determinants of antimicrobial drug resistance in *Pseudomonas aeruginosa*.
Antimicrob Agents Chemother 2009;**53**: 2522-2531.

Tables

Table 1. Summary of antimicrobial resistance prevalence across 10 clinically relevant antibiotics in

the *Pseudomonas aeruginosa* Global Dataset

Antibiotic Class	Antibiotic	Res (%)	Int (%)	Sen (%)	No. isolates
Carbapenems	MEM	637 (46)	119 (9)	632 (46)	1388
	IPM	126 (76)	6 (4)	33 (20)	165
Polymyxins	CST	27 (4)	0 (0)	665 (96)	692
Fluoroquinolones	CIP	446 (61)	59 (8)	228 (31)	733
Cephalosporins	FEP	146 (33)	75 (17)	221 (50)	442
	CAZ	297 (43)	108 (16)	279 (41)	684
Penicillins	TZP	142 (52)	25 (9)	104 (38)	271
	PIP	179 (57)	23 (7)	113 (36)	315
Aminoglycosides	TOB	269 (38)	10 (1)	433 (61)	712
	AMK	166 (18)	52 (6)	721 (77)	939

459 Abbreviations: Res, resistant; Int, intermediate; Sen, sensitive; MEM, meropenem; IPM, imipenem;

460 CST, colistin; CIP, ciprofloxacin; FEP, cefepime; CAZ, ceftazidime, TZP, piperacillin/tazobactam; PIP,

461 piperacillin; TOB, tobramycin; AMK, amikacin

462   **Table 2. Novel antimicrobial resistance (AMR) determinants identified in *Pseudomonas aeruginosa***

463   **by microbial genome-wide association study (mGWAS) and comparative genomic analyses**

Locus	Type of mutation	Associated AMR phenotype	Fisher's Exact p value
PA0027	Lys34Asn	PIPr	< 0.0001
PA0295	Ala155Thr	MEMi	< 0.0001
PA0746	Lys106Asn	FEPr	< 0.0001
PA0799	Ala275Thr	PIPr	< 0.0001
PA0807 (*ampDh3*)	Ser44Arg	IPMr	0.5545
PA0946	Arg287Trp	CAZr	< 0.0001
PA0958 (*oprD*)	Gln340Pro	MEMr	1
PA0958 (*oprD*)	Leu136Gln	MEMr	1
PA0958 (*oprD*)	Leu409Pro	MEMr	1
PA1017 (*pauA*)	LOF	CAZr, MEMi	NA
PA1045	Lys322Arg	FEPr	< 0.0001
PA1760	LOF	MEMr, TZPi	NA
PA1798 (*parS*)	Ala149Thr	MEMr	< 0.0001
PA1798 (*parS*)	Arg383Cys	CSTr	0.039
PA1798 (*parS*)	Arg7His	PIPr	1
PA1798 (*parS*)	Asp249Asn	TZPr, AMKi	0.1399, 0.0003
PA1799 (*parR*)	Leu165Phe	MEMr	1
PA1799 (*parR*)	Val68Ala	CAZr	0.0309
PA1923	Ala350Val	TZPr	< 0.0001
PA1942*	LOF	MEMr	NA
PA1997	Ile54Val	TZPr	< 0.0001
PA2020	Leu199Arg	FEPr	0.3978
PA2020	Ser198Ile	MEMr	1
PA2020	Thr32Asn	MEMr	0.4996
PA2064 (*pcoB*)	Gln59Lys	FEPr	< 0.0001
PA2252	LOF	TZPi	NA
PA2402	Val3040Ala	AMKr	< 0.0001
PA2519 (*xylS*)	Thr242Pro	AMKr	0.0349
PA2520 (*czcA*)	Gly1051Asp	CSTr	0.039
PA2567	Ile508Val	TZPr	< 0.0001
PA2727	Arg383Gln	TZPr	< 0.0001
PA2736	Arg30Gly	AMKr	< 0.0001
PA3083 (*pepN*)	LOF	MEMr, AMKr	NA
PA3384 (*phnC*)	LOF	MEMr, TOBr	NA
PA3418 (*ldh*)	LOF	MEMr	NA
PA3574 (*nalD*)	Arg164Pro	PIPr, FEPr	1, 0.3978
PA3574 (*nalD*)	Leu76Pro	MEMr	1
PA3721 (*nalC*)	Lys58Glu	MEMr	1
PA4020 (*mpl*)	Gly137Ser	CAZr	1
PA4020 (*mpl*)	Thr115Asn	MEMr, IPMr	0.4896, 1
PA4109 (*ampR*)	Asp135Gly	PIPr	0.2859

PA4109 (ampR)	Ter297Tyrext*?	PIPr	0.0006
PA4110 (ampC)	Asp272Asn	MEMr	1
PA4110 (ampC)	Leu320Pro	MEMr	1
PA4260 (rplB)	Gly138Asp	AMKr	0.0223
PA4260 (rplB)	Gly138Ser	TOBr, AMKr	1, 0.1871
PA4266 (fusA1)#	Arg658His	TOBr, AMKr	< 0.0001, < 0.0001
PA4296 (pprB)	Asn253His	CSTr	0.039
PA4318	Pro243Ser	PIPr	< 0.0001
PA4418 (ftsI)	Gly63Asp	MEMr, IPMr, CAZr, FEPr, TZPr, PIPr	1, 1, 1, 1, 1, 1
PA4464 (ptsN)	Pro10_Gly11dup	IPMr	1
PA4522 (ampD)	Gly100Glu	MEMr	1
PA4522 (ampD)	Gly116Val	MEMr	1
PA4522 (ampD)	Gly121Glu	MEMr	0.374
PA4522 (ampD)	Ile117Thr	CAZr	1
PA4522 (ampD)	Ile69Thr	MEMr	1
PA4522 (ampD)	Pro41Leu	PIPr	1
PA4522 (ampD)	Val10Gly	CAZr, FEPi	0.0114, 0.0003
PA4522 (ampD)	Pro41Leu	FEPr	0.3978
PA4522 (ampD)	Gly169Cys	FEPr	0.3978
PA4522 (ampD)	Cys110Gly	FEPr	0.1576
PA4522 (ampD)	Gly116Val	CAZr	1
PA4522 (ampD)	Gln88Leu	CAZr	0.4996
PA4522 (ampD)	His157Tyr	CAZr	0.2494
PA4531	Lys17Arg	PIPr	< 0.0001
PA4622	Ile380Val	FEPr	< 0.0001
PA4677	Asp138Val	FEPr	< 0.0001
PA4692	Ala180Val	PIPr	< 0.0001
PA4776 (pmrA)	Leu72Phe	CSTr	0.039
PA4777 (pmrB)	Arg155His	CSTr	0.039
PA4777 (pmrB)	Thr253Met	CSTr	0.039
PA4777 (pmrB)	Thr158Ile	CSTr	0.039
PA4777 (pmrB)	Arg10Leu	CSTr	0.039
PA4778 (cueR)	Gly57Ala	CSTr	0.039
PA5000 (wapR)	Gly163Asp	CSTr	0.039
PA5192 (pckA)	Ala461Thr	FEPr	< 0.0001
PA5199 (amgS)	Pro435Ala	CSTr	0.039
PA5199 (amgS)	Trp120Gly	CSTr	0.039
PA5338 (spoT)	Gly496Ser	CAZr	1
PA5493 (polA)	Lys395Arg	AMKr	< 0.0001

Abbreviations: AMK, amikacin; CAZ, ceftazidime; CIP, ciprofloxacin; CST, colistin; FEP, cefepime; i,
intermediate resistant; IPM, imipenem; LOF, loss of function; MEM, meropenem; PIP, piperacillin; r,
resistant; TOB, tobramycin; TZP, piperacillin/tazobactam

*Previously predicted to cause PIPr;[30] however, mGWAS did not identify a significant association with
this phenotype. Instead, mGWAS showed that this AMR determinant was significantly associated with
MEMr

#Identified in the Validation Dataset only.

 Figures

Figure 1. Balanced accuracy (bACC) of ARDaP, ResFinder, and AMRFinderPlus for antimicrobial

resistance (AMR) prediction in the (A) Global *Pseudomonas aeruginosa* Dataset (n=1391 isolates),

and (B) Validation *P. aeruginosa* Dataset (*n*=89 isolates), across ten clinically relevant antibiotics. To

enable comparison with existing AMR prediction software, isolates with intermediate AMR were

removed prior to analysis. Abbreviations: AMK, amikacin; CAZ, ceftazidime; CIP, ciprofloxacin; CST,

colistin; FEP, cefepime; FQs, fluoroquinolones; IPM, imipenem; MEM, meropenem; PIP, piperacillin;

TZP, piperacillin/tazobactam; TOB, tobramycin. *No strains in the Validation Dataset exhibited CST

AMR; as such, bACC could not be calculated for this antibiotic.